CN102341126A - 用于磁共振成像的钆表现脂质纳米颗粒 - Google Patents

用于磁共振成像的钆表现脂质纳米颗粒 Download PDF

Info

Publication number
CN102341126A
CN102341126A CN2010800105605A CN201080010560A CN102341126A CN 102341126 A CN102341126 A CN 102341126A CN 2010800105605 A CN2010800105605 A CN 2010800105605A CN 201080010560 A CN201080010560 A CN 201080010560A CN 102341126 A CN102341126 A CN 102341126A
Authority
CN
China
Prior art keywords
compositions
lipid
dtpa
chelate
metallo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800105605A
Other languages
English (en)
Chinese (zh)
Inventor
R·J·Y·霍
J·D·霍克曼
K·马拉维拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Priority to CN201610996986.1A priority Critical patent/CN106362171A/zh
Publication of CN102341126A publication Critical patent/CN102341126A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0408—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1227—Micelles, e.g. phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
CN2010800105605A 2009-02-13 2010-02-16 用于磁共振成像的钆表现脂质纳米颗粒 Pending CN102341126A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610996986.1A CN106362171A (zh) 2009-02-13 2010-02-16 用于磁共振成像的钆表现脂质纳米颗粒

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15245909P 2009-02-13 2009-02-13
US61/152,459 2009-02-13
US16298909P 2009-03-24 2009-03-24
US61/162,989 2009-03-24
PCT/US2010/024324 WO2010094043A2 (en) 2009-02-13 2010-02-16 Gadolinium expressed lipid nanoparticles for magnetic resonance imaging

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610996986.1A Division CN106362171A (zh) 2009-02-13 2010-02-16 用于磁共振成像的钆表现脂质纳米颗粒

Publications (1)

Publication Number Publication Date
CN102341126A true CN102341126A (zh) 2012-02-01

Family

ID=42562321

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610996986.1A Pending CN106362171A (zh) 2009-02-13 2010-02-16 用于磁共振成像的钆表现脂质纳米颗粒
CN2010800105605A Pending CN102341126A (zh) 2009-02-13 2010-02-16 用于磁共振成像的钆表现脂质纳米颗粒

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610996986.1A Pending CN106362171A (zh) 2009-02-13 2010-02-16 用于磁共振成像的钆表现脂质纳米颗粒

Country Status (5)

Country Link
US (2) US20120087857A1 (enExample)
EP (1) EP2398503B1 (enExample)
JP (2) JP5847588B2 (enExample)
CN (2) CN106362171A (enExample)
WO (1) WO2010094043A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151650A1 (en) * 2012-04-05 2013-10-10 University Of Florida Research Foundation, Inc. Neurophilic nanoparticles
WO2016073348A1 (en) * 2014-11-03 2016-05-12 Albert Einstein College Of Medicine, Inc. Modified paramagnetic nanoparticles for targeted delivery of therapeutics and methods thereof
GB201509934D0 (en) 2015-06-08 2015-07-22 King S College London Nanoparticles
CN120392779A (zh) * 2015-06-15 2025-08-01 华盛顿大学 用于延长血液和淋巴组织中的药物水平的多药脂质纳米颗粒组合物和相关方法
CN107412790B (zh) * 2017-09-08 2019-02-22 丽水市中心医院 一种核磁共振纳米材料的制备方法
EP3787696A4 (en) 2018-04-30 2022-05-18 Bar-Ilan University POLYMERIC CORE-SHELL PARTICLES
US20200261605A1 (en) * 2019-01-24 2020-08-20 Alzeca Biosciences, LLC Functionalized liposomes for imaging misfolded proteins
JP7395759B2 (ja) * 2020-01-29 2023-12-11 テキサス チルドレンズ ホスピタル アミロイド沈着のｍｒｉのための標的造影剤
CN113730614B (zh) * 2021-09-09 2022-02-22 南京市第一医院 一种镥标记的纳米载体及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1535163A (zh) * 2001-05-30 2004-10-06 ˹������˹�о�ѧԺ 核酸传递系统
US20050112065A1 (en) * 2003-07-09 2005-05-26 Drummond Daryl C. Remote detection of substance delivery to cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833948A (en) 1995-06-15 1998-11-10 Bracco Research S.A. Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant
EP1105162A1 (en) * 1998-08-10 2001-06-13 Bracco Research S.A. Combination of a positive mri contrast agent with a negative mri contrast agent
US20030082103A1 (en) * 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US7459145B2 (en) * 2002-10-25 2008-12-02 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
CN1897978B (zh) * 2003-12-22 2011-11-23 博莱科瑞士股份有限公司 具有用于反差成像的活性组分的充气微囊组件
EP2325642A1 (en) * 2004-04-20 2011-05-25 Emory University Use of multimodality nanostructures to detect target substances
EP1827506A2 (en) * 2004-12-17 2007-09-05 Koninklijke Philips Electronics N.V. Targeting contrast agents or targeting therapeutic agents for molecular imaging and therapy
US8753673B2 (en) * 2006-05-23 2014-06-17 Taiwan Liposome Co. Ltd. Liposome composition for delivery of a therapeutic agent to eyes
CA2680206C (en) * 2007-03-05 2015-07-07 Washington University Nanoparticle delivery systems for membrane-integrating peptides
KR20080094473A (ko) * 2007-04-20 2008-10-23 한국화학연구원 음이온성 지질나노입자 및 이의 제조방법
US20110027172A1 (en) * 2007-12-10 2011-02-03 Zhuang Wang Drug delivery system for pharmaceuticals and radiation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1535163A (zh) * 2001-05-30 2004-10-06 ˹������˹�о�ѧԺ 核酸传递系统
US20050112065A1 (en) * 2003-07-09 2005-05-26 Drummond Daryl C. Remote detection of substance delivery to cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SJOERD HAK ET AL: "A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging", 《EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS》, vol. 72, 10 October 2008 (2008-10-10) *

Also Published As

Publication number Publication date
US20170173190A1 (en) 2017-06-22
WO2010094043A2 (en) 2010-08-19
EP2398503A2 (en) 2011-12-28
US11207430B2 (en) 2021-12-28
CN106362171A (zh) 2017-02-01
EP2398503B1 (en) 2018-10-31
JP5847588B2 (ja) 2016-01-27
JP2012518012A (ja) 2012-08-09
EP2398503A4 (en) 2015-05-06
JP6072205B2 (ja) 2017-02-01
US20120087857A1 (en) 2012-04-12
WO2010094043A3 (en) 2011-01-06
JP2016094425A (ja) 2016-05-26

Similar Documents

Publication Publication Date Title
JP6072205B2 (ja) 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子
Remsen et al. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis.
Kojima et al. Dendrimer-based MRI contrast agents: the effects of PEGylation on relaxivity and pharmacokinetics
Okuhata Delivery of diagnostic agents for magnetic resonance imaging
Mao et al. Functional nanoparticles for magnetic resonance imaging
EP0247156B1 (en) Polychelating agents for image and spectral enhancement (and spectral shift)
Yang et al. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging
Veiseh et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier
Barrett et al. Macromolecular MRI contrast agents for imaging tumor angiogenesis
Corbin et al. Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents
Jia et al. Active-target T1-weighted MR imaging of tiny hepatic tumor via RGD modified ultra-small Fe3O4 nanoprobes
US8361494B2 (en) Biomimetic iron-oxide-containing lipoprotein and related materials
Trubetskoy et al. New approaches in the chemical design of Gd-containing liposomes for use in magnetic resonance imaging of lymph nodes
US6468505B1 (en) Technique to monitor drug delivery noninvasively in vivo
WO2006003731A1 (ja) 高分子ミセル型ｍｒｉ造影剤
US20090317327A1 (en) Aqueous Dispersion of Superparamagnetic Single-Domain Particles, Production and Use Thereof in Diagnosis and Therapy
Yan et al. Research progress of magnetic resonance imaging contrast agents
Fu et al. Gadolinium (iii) complex-backboned branched polymers as imaging probes for contrast-enhanced magnetic resonance angiography
Ma et al. Deposition of gadolinium onto the shell structure of micelles for integrated magnetic resonance imaging and robust drug delivery systems
Iqbal et al. Small unilamellar vesicles: a platform technology for molecular imaging of brain tumors
JP6852080B2 (ja) 混合シクロデキストリン種を担持するポリロタキサン、およびその使用
Huang et al. Gadolinium-conjugated star-block copolymer polylysine-modified polyethylenimine as high-performance T 1 MR imaging blood pool contrast agents
Karathanasis et al. MRI mediated, non-invasive tracking of intratumoral distribution of nanocarriers in ratglioma
US20140363378A1 (en) Self-assembling molecules that accumulate in acidic tumor microenvironments
KR20120045690A (ko) 최적의 글루콘산 도입으로 향상된 생체 적용능을 확보한 글루콘산과 비고분자 생체 존재물질이 표면개질제로 도입된 산화철 나노입자 및 이를 포함한 암 진단 및 치료용 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120201